🎥 @DrAEvens of @RutgersCancer shares insights into the HoLISTIC Consortium, a global NIH-funded initiative that has aggregated data from over 30,000 patients with #HodgkinLymphoma.

Learn more by clicking here:

👉 👈

#18ICML #LYMsm #Lymphoma #HemOnc

Insights into the HoLISTIC Consortium & the value of this initiative

Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares insights into the HoLISTIC Consortium, a ...

ow.ly

It was a pleasure to speak with the lovely @helgasimonm of @amsterdamumc at #iwCLL2025 to hear about her work investigating the metabolic fitness of T-cells in patients with CLL.🩸🔬

Click here to learn more:

👉 👈

#CLLsm #Leusm #Leukemia #ImmunoOnc…

Investigating the metabolic fitness of T-cells in patients with CLL

In this video, Helga Simon-Molas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, discusses her work i...

ow.ly

We recently spoke with @aaronchengmd (@PennMedicine), who shared insights from an analysis of morbidity rates in adults with non-transfusion-dependent #thalassemia referred to three US specialty centers.

Watch the interview here:

👉 👈

#Hematology

Examining the morbidity rate in adults with NTDT referred to US specialty centers

Aaron Cheng, MD, University of Pennsylvania, Philadelphia, PA, discusses the high morbidity rate in adults with non-tr...

ow.ly

At #SOHO2025, we spoke with @khouri_jack of @ClevelandClinic, who discussed the safety & efficacy of the novel BCL-2 inhibitor lisaftoclax in different combinations for patients with #MultipleMyeloma or AL #amyloidosis.🩸

Watch the interview here:

👉 👈…

Lisaftoclax combinations in R/R myeloma and AL amyloidosis

Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses the safety and efficacy of the novel BCL-2 inhibitor lis...

ow.ly